Lipocine
LPCN
37 hedge funds and large institutions have $7.63M invested in Lipocine in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 15 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
6.55% less ownership
Funds ownership: 42.72% → 36.17% (-6.6%)
21% less funds holding
Funds holding: 47 → 37 (-10)
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
71% less capital inflows, than outflows
Capital inflows: $2.13M | Capital outflows: $7.38M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squadron Capital Management
Westmont,
Illinois
|
+$866K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$410K |
| 3 |
Jane Street
New York
|
+$181K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$125K |
| 5 |
Two Sigma Investments
New York
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$1.77M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.6M |
| 3 |
Stempoint Capital
New York
|
-$1.28M |
| 4 |
MBAM
Mink Brook Asset Management
West Palm Beach,
Florida
|
-$534K |
| 5 |
Exome Asset Management
New York
|
-$486K |
LPCN Hedge Fund Activity: Q2 2026 in Review
37 of the 8,372 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2026, worth a combined $7.63M — down 69% from $24.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LPCN and 5 opened new positions — a net loss of 10 holders — while 3 trimmed existing stakes and 14 added.
The largest buyer was Squadron Capital Management, adding an estimated $866K. The largest seller was Rosalind Advisors, exiting entirely with an estimated $1.77M sold.
- 37 institutional investors held Lipocine (LPCN) as of Q2 2026, down from 47 in Q1 2026.
- Funds reported $7.63M of Lipocine stock for Q2 2026, down 69% quarter-over-quarter.
- 5 funds opened new Lipocine positions in Q2 2026 and 15 closed out, a net change of -10 holders.
- The largest Lipocine buyer in Q2 2026 was Squadron Capital Management, an estimated $866K added.
- The largest Lipocine seller in Q2 2026 was Rosalind Advisors, an estimated $1.77M sold.
Based on aggregated 13F filings for Q2 2026.